Fabhalta (iptacopan) Lutathera (lutetium Lu 177 dotatate) In line with our strategic focus on oncology, Novartis acquired >90% of the total share capital of MorphoSys AG, adding to our pipeline pelabresib, a late-stage investigational BET inhibitor for myelofibrosis, and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas. Coartem (artemetherlumefantrine) Net income was USD 3.2 billion (+43%, +49% cc), mainly driven by higher operating income. EPS was ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ...

C3G Disease Overview - C3G is a rare kidney disease with no specifically approved therapies, leading most patients to progress to kidney failure requiring dialysis or transplant [8] - Current treatments are complex and burdensome, often involving combinations of antihypertensive agents, SGLT2 inhibitors, corticosteroids, and immunosuppressive agents [9] - Nephrologists adjust treatment approaches based on eGFR decline and proteinuria levels, with SGLT2 inhibitor use increasing year-over-year [9] Physician Perspectives and Challenges - 148 nephrologists across EU5 countries emphasize the urgent need for effective C3G treatments and the importance of early intervention [1] - Less than half of EU5 nephrologists feel confident in achieving target proteinuria levels with current treatments [2] - Over 75% of audited C3G patients are expected to progress to end-stage renal disease within the next decade [2] Emerging Treatment Landscape - Promising new treatments in development include Novartis' Fabhalta (iptacopan) and Apellis' Empaveli (pegcetacoplan) [3] - Phase III APPEAR-C3G study showed Fabhalta plus supportive care achieved a 35.1% reduction in proteinuria at 6 months compared to placebo [10] - Additional pipeline assets from Q32 Bio, Omeros, and others offer hope for better C3G management [3] Market Research and Insights - Spherix's Patient Chart Dynamix™ service analyzes real patient management patterns and treatment decision drivers [4] - Market Dynamix™ provides analysis of markets expected to experience paradigm shifts in 3-5 years, including C3G [12] - Spherix monitors specialty markets across multiple therapeutic areas through its extensive Physician Community [13]

That's where the Style Scores come in. To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible. The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Growth investors are more concerned with a stock's future prospects, and the overall financial heal ...

Novartis AG (NYSE:NVS) Investor Event at ASCO Conference Call June 2, 2024 7:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global Head of Oncology & Hematology Drug Development Reshema Kemps-Polanco - Chief Commercial Officer of U.S. Business Rodney Gillespie - International Therapeutic Area Head, Oncology Novartis Conference Call Participants Emmanuel Papadakis - Deutsche Bank Steve Scala - TD ...

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1 Remibrutinib, an oral Bruton's tyrosine kinase inhibitor, demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo1 Novartis intends to submit remibrutinib for approval in chronic spontaneous urticaria (CSU) to global health authorities starting in H2 2024, and continues to inve ...

Novartis (NVS) announced results from the six-month, double-blind trial period of the late-stage APPEAR- C3G study of Fabhalta. Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, is being investigated in adult patients with C3 glomerulopathy (C3G). APPEAR-C3G is a phase III multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of twice-daily oral Fabhalta (200 mg) in C3G patients. The study comprises a six-month double-bl ...

Core Viewpoint - Novartis is currently performing well despite a recent decline in net sales due to the spin-off of its Sandoz business, with strong growth in continuing operations and a positive outlook for future earnings and dividends [3][11][35] Financial Performance - Q1 2023 net sales were $12.953 billion, a 3% increase year-over-year, while Q1 2024 net sales decreased to $11.829 billion, an 8.7% decline due to the Sandoz spin-off [6][9] - Adjusted for the spin-off, net sales from continuing operations grew by 9.5% year-over-year in Q1 2024, with currency-neutral net sales increasing by 11% [11] - Core EPS for Q1 2024 rose by 16.9% to $1.80, exceeding analyst expectations [14] Growth Drivers - Novartis' top 20 brands saw net sales increase by 16% to $9.3 billion in Q1 2024, with 13 out of 20 brands experiencing growth [12][13] - The company has over 100 projects in clinical development and plans to submit more than two dozen indications in core therapeutic areas to regulatory authorities [16][17] Debt and Financial Health - Net debt increased from $10.2 billion to $15.8 billion, primarily due to a $5.2 billion annual dividend payment, but remains manageable [19] - Novartis maintains an AA- credit rating from S&P, indicating strong financial health and stability [20] Valuation and Dividend - Current P/E ratio is 13.8, below the 10-year average of 16.3, suggesting the stock is undervalued [22] - The forward dividend yield is 3.7%, significantly higher than the healthcare sector median of 1.5%, with a consistent annual growth of 6.9% over the last five years [28][30]